

ten23 health joins the “Alliance for RTU” - an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing

- “The Alliance for RTU” was founded in September 2024 by leading primary packaging manufacturers Gerresheimer (MDAX: GXI), SCHOTT Pharma (SDAX: 1SXP), and Stevanato Group (NYSE: STVN)
- The alliance will advance technical exchange and scientific developments related to ready-to-use (RTU) containers for sterile filling
- The long-term aim is to transition to high-quality sterile packing, enhancing operational efficiency and patient safety

June 30, 2025, Basel, Switzerland - ten23 health, the human-centric and sustainable strategic CDTMO partner of choice for the pharmaceutical industry and biotech start-ups, has joined the „Alliance for RTU“, an association to advance technical exchange for ready-to-use (RTU) containers in sterile manufacturing. The Alliance for RTU was formed in response to the market need for aseptic filling technologies and processes. It provides an expert platform to share expertise and technical knowledge on high-quality ready-to-fill sterile primary packaging with pharmaceutical companies, CMOs and CDMOs.

The vast experience of ten23 health in the development, sterile fill & finish (sterile manufacturing), and testing of sterile drug products using RTU container platforms makes the company a valuable addition to the Alliance. While RTU containers are an established format for syringes, the configuration also provides ample opportunities for vials and cartridges, as certain challenges persist for those container types.

By contributing the knowledge and expertise gained through a wide range of customer projects, ten23 aims to facilitate the further development and standardization of RTU

container platforms. This will improve efficiency and quality, while supporting regulatory compliance and promoting patient well-being.

About ten23 health

ten23 health®, located in Basel and Visp, Switzerland, is the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test modern medicines. We support our clients in developing differentiated, stable, usable, and safe injectable treatment options for patients. ten23 health® combines the latest scientific findings with proven and tested world-class industry and regulatory expertise to forge new paths for supporting clients. We provide our innovative services in a fair and sustainable manner, respecting people's health and the future of our planet. ten23 health® is a B Corp member and solidly financed through the long-term commitment of 3i Group, an internationally reputable equity partner.

About the company's name

The numeric value for the number of molecules in a sample of one mol is called Avogadro constant and equals $6.022 \cdot 10^{23}$. Gram quantities of material contain the incredible number of 10^{23} atoms, which was an important discovery to understand the composition of matter: The world is built from small units, and not a homogeneous mass.

About 3i Group

3i is an investment company with two complementary businesses, Private Equity and Infrastructure, and invests in mid-market companies headquartered in Europe and North America. 3i's Private Equity team provides investment solutions for growing companies, backing entrepreneurs and management teams of companies with an EV typically between €100m - €500m. 3i backs international growth plans, providing access to its network and expertise to accelerate the growth of companies across the consumer, healthcare, industrial and private label, and services and software industries.

About Gerresheimer

Gerresheimer is an innovative systems and solutions provider and a global partner for the pharma, biotech and cosmetic industries. The Group offers a comprehensive portfolio of drug containment solutions including closures and accessories, as well as drug delivery systems, medical devices and solutions for the health industry. The product range includes digital solutions for therapy support, medication pumps, syringes, pens, auto-injectors and inhalers as well as vials, cartridges, ampoules, tablet containers, infusion, dropper and syrup bottles and more. Gerresheimer ensures the safe delivery and reliable administration of drugs to the patient. Gerresheimer supports its customers with comprehensive services along the value chain and in addressing the growing demand for enhanced sustainability. With over 40 production sites in 16 countries in Europe, America and Asia, Gerresheimer has a global presence and produces locally for regional markets. Together with Bormioli Pharma 2024, the Group generated revenues of around EUR 2.4bn and currently employs around 13,400 people. Gerresheimer AG is listed in the MDAX on the Frankfurt Stock Exchange (ISIN: DE000A0LD6E6) Further information at www.gerresheimer.com

About SCHOTT Pharma

Human health matters. That is why SCHOTT Pharma designs solutions grounded in science to ensure that medications are safe and easy to use for people around the world. Every minute, more than 25,000 people receive an injection packed in a SCHOTT Pharma product. The portfolio comprises drug containment solutions and delivery systems for injectable drugs ranging from prefillable glass and polymer syringes to cartridges, vials, and ampoules. Every day, a team of around 4,700 people from over 60 nations works at SCHOTT Pharma to contribute to global healthcare. The company is represented in all main pharmaceutical hubs with 17 manufacturing sites in Europe, North and South America, and Asia. With over 1,000 patents and technologies developed in-house and a state-of-the-art R&D center in Switzerland, the company is focused on developing innovations for the future. SCHOTT Pharma AG & Co. KGaA is headquartered in Mainz, Germany and listed on

the Frankfurt Stock Exchange as part of the SDAX. It is majority owned by SCHOTT AG, which is owned by the Carl Zeiss Foundation. In light of this spirit, SCHOTT Pharma is committed to sustainable development for society and the environment. Currently, SCHOTT Pharma has over 1,800 customers including the top 30 leading pharma manufacturers for injectable drugs and generated revenue of EUR 957 million in the fiscal year 2024. Further information at www.schott-pharma.com

About Stevanato Group

Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group's core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.

To learn more about the Alliance for RTU, visit www.alliance-for-rtu.com or contact info@alliance-for-rtu.com.

Media contacts:

ten23 health: Mara Willa mara.willa@ten23.health; Marija Petrovic marija.petrovic@ten23.health

3i Group: Kathryn van der Kroft, Kathryn.VanDerKroft@3i.com